

Table of Contents

| | |
|---|----------|
| 1. Introduction | 1 |
| 2. Assay Principle | 1 |
| 3. Kits and Components | 3 |
| 4. Materials Required but Not Supplied | 3 |
| 5. Performing the Assay | 4 |
| 5.1 Preparing the Assay Reagents | 4 |
| 5.2 Generating a Kinase Titration | 4 |
| 5.3 Kinase Kinetic Activity Analysis | 5 |
| 5.4 K_m and V_{max} Data Analysis | 6 |
| 5.5 Determining Kinase Inhibitor IC_{50} Values | 7 |
| 5.6 Compound Interference | 8 |
| 6. References | 9 |

1. Introduction

Protein kinases make up one of the largest human gene families, with 518 human protein kinases identified. As critical components of cellular signal transduction cascades, these enzymes regulate many essential biological mechanisms, including proliferation, differentiation, metabolism, and cell growth. A wide variety of human diseases have been linked to aberrant kinase activity. The ability to determine kinase activity and the effects of compounds that modulate this activity is essential for the development and screening of potential drugs against these enzymes.


Omnia[®] Kinase Assays provide a fluorescence peptide substrate-based assay for the rapid, homogeneous, and sensitive detection of serine/threonine or tyrosine kinase enzymatic activity. Omnia[®] kinase assays can be used for a variety of applications, including kinetic studies, IC_{50} determinations, and kinase inhibitor screening. Forty-six different peptide substrates are available that can be used to measure the kinase activity of 193 different kinases (see reactivity table at www.invitrogen.com/omnia). Using these assays, you can measure kinase reactions under optimal kinetics, physiological (mM) ATP, and in real time without the use of radioactive tracers or specialized equipment. Omnia[®] assays directly measure the activity of the target enzyme without use of beads or secondary detection steps involving antibodies or enzymes. Because the assay can be performed with a wide range of ATP concentrations, including physiological (mM) levels, Omnia[®] assays can be used to select for both ATP competitive and ATP non-competitive (allosteric) kinase inhibitors.

2. Assay Principle

Omnia[®] Kinase Assays use the chelation-enhanced fluorophore (CHEF) 8-hydroxy-5-(N,N-dimethylsulfonamido)-2-methylquinoline (referred to as Sox^{1,2}). Sox is an unnatural amino acid that can be prepared as an Fmoc-protected derivative. This is incorporated into the substrate peptide using standard solid-phase peptide chemistry.

Upon phosphorylation of the peptide by a kinase, Mg^{2+} is chelated to form a bridge between the Sox moiety and the incorporated phosphate group on the serine, threonine, or tyrosine residue within the peptide (Figure 1). This results in an increase in fluorescence when the kinase reaction mixture is excited at 360 nm and the emission is measured at 485 nm, as shown in the following figure.

A. Mechanism of the Assay



B. Emission Spectra




Figure 1: **A.** Schematic view of Mg^{2+} chelation by Sox and the phosphate group on a phosphorylated serine, threonine, or tyrosine residue. **B.** Fluorescence emission spectra of a Sox peptide substrate (lower) and a Sox phosphopeptide product (upper) in the presence of $MgCl_2$ generated using a constant excitation wavelength of 360 nm. The non-phosphorylated version of the Sox-modified peptide has a very low affinity for Mg^{2+} ($K_d = 100\text{--}300\text{ mM}$). The affinity for Mg^{2+} increases dramatically upon phosphorylation ($K_d = 4\text{--}20\text{ mM}$). Therefore, upon phosphorylation, most of the phosphopeptide exists in the Mg^{2+} -chelated, fluorescent state in the presence of $MgCl_2$.

3. Kits and Components

This user guide covers the following kits:

| Omnia® Kinase Assay Kit | Catalog no. |
|-------------------------|-------------|
| Ser/Thr 1 | KNZ1011 |
| Ser/Thr 2 | KNZ1021 |
| Ser/Thr 3 | KNZ1031 |
| Ser/Thr 4 | KNZ1041 |
| Ser/Thr 5 | KNZ1051 |
| Ser/Thr 6 | KNZ1061 |
| Ser/Thr 7 | KNZ1071 |
| Ser/Thr 8 | KNZ1081 |
| Ser/Thr 9 | KNZ1091 |
| Ser/Thr 10 | KNZ1101 |
| Ser/Thr 11 | KNZ1111 |
| Ser/Thr 12 | KNZ1121 |
| Ser/Thr 13 | KNZ1131 |
| Ser/Thr 14 | KNZ1141 |
| Ser/Thr 15 | KNZ1151 |
| Ser/Thr 16 | KNZ1161 |
| Ser/Thr 17 | KNZ1171 |
| Ser/Thr 18 | KNZ1181 |
| Ser/Thr 19 | KNZ1191 |
| Ser/Thr 20 | KNZ1201 |
| Ser/Thr 21 | KNZ1211 |
| Ser/Thr 22 | KNZ1221 |
| Ser/Thr 23 | KNZ1231 |

| Omnia® Kinase Assay Kit | Catalog no. |
|-------------------------|-------------|
| Ser/Thr 24 | KNZ1241 |
| Ser/Thr 25 | KPZ1251 |
| Ser/Thr 26 | KPZ1261 |
| Ser/Thr 27 | KNZ1271 |
| Ser/Thr 28 | KNZ1281 |
| Ser/Thr 29 | KPZ1291 |
| Ser/Thr 30 | KPZ1301 |
| Ser/Thr 31 | KPZ1311 |
| Ser/Thr 32 | KNZ1321 |
| Tyr 1 | KNZ3011 |
| Tyr 2 | KNZ3021 |
| Tyr 3 | KNZ3031 |
| Tyr 4 | KNZ3041 |
| Tyr 5 | KNZ3051 |
| Tyr 6 | KNZ3061 |
| Tyr 7 | KNZ3071 |
| Tyr 8 | KNZ3081 |
| Tyr 9 | KNZ3091 |
| Tyr 10 | KNZ3101 |
| Tyr 11 | KNZ3111 |
| Tyr 12 | KPZ3121 |
| Tyr 13 | KNZ3131 |
| Tyr 14 | KPZ3141 |

Each kit provides sufficient reagents to run two 384-well assay plates at a 20-µL final assay volume.

| Catalog Number | Component | Description | Amount |
|------------------|------------------------------|----------------------------------|--------|
| Various | Omnia® Peptide | Omnia® peptide, 1 mM | 220 µL |
| AS001A | ATP Solution | 100 mM ATP in 20 mM Tris, pH 7.5 | 1 mL |
| P2325 | DTT Solution | 1 M DTT in water | 1 mL |
| KB001A or KB002A | Kinase Reaction Buffer (10X) | Proprietary buffer, pH 7.5 | 10 mL |

4. Materials Required but Not Supplied

- Recombinant kinase of interest (visit www.invitrogen.com/kinases for a list of Invitrogen kinases).
- Fluorescence microplate reader capable of reading λ_{ex} 360/ λ_{em} 485 in a kinetic manner.

Note: Omnia® assays have been run on instruments such as the Tecan Safire 2™, Infinite® M1000, Infinite® F500, Molecular Device SpectraMax® M5, BMG LABTECH PHERAstar, FLUOstar OPTIMA, BioTek FLx800™, Synergy™ 2, and Synergy™ 4, and ThermoFisher Varioskan. Contact Drug Discovery Technical Support or e-mail us directly at drugdiscovertech@invitrogen.com for instrument-specific setup guidelines.

- Precision pipettes with disposable plastic tips that can accurately deliver volumes of 2–20 µL.
- Ultrapure deionized H₂O.
- Plastic tubes with low protein binding for diluting and aliquoting assay components.
- White (Corning 3574) or Black (Corning 3676) Microtiter plates. Other plates, while not tested, may be suitable.

Technical Support for this or other Drug Discovery Products, dial 760-603-7200, option 3, extension 40266

5. Performing the Assay

Kinase reactions can be run in a 384-well or 96-well plate. The reaction is initiated by addition of the Master Mix to the kinase of interest. Since the assay is a homogeneous, single-step format, no washing steps, stop solutions or additional components are required. The assay is simply conducted at 30°C and fluorescence measurements are recorded using either kinetic readings (e.g., readings every 30 seconds for 60 minutes as the assay progresses) or a single endpoint reading after the assay is complete.

5.1 Preparing the Assay Reagents

Prior to setting up the individual reactions, prepare the following solutions:

1. **Peptide Substrate (10X):** Prepare a 100 μ M (10X) peptide stock by adding 2 μ L of the 1 mM stock to 18 μ L of ultrapure water.
2. **ATP Solution (10X):** Prepare a 10 mM (10X) ATP solution by adding 2 μ L of 100 mM ATP to 18 μ L ultrapure water.
3. **DTT Solution (10X):** Prepare a 2 mM (10X) DTT solution by adding 2 μ L of 1 M DTT to 998 μ L ultrapure water.
4. **Kinase Reaction Buffer (1X):** Prepare a 1X Kinase Reaction Buffer solution by adding 0.5 mL of 10X Kinase Reaction Buffer to 4.5 mL of ultrapure water.

5.2 Generating a Kinase Titration

The amount of kinase used in an Omnia® assay is highly dependent on the specific activity of the kinase towards a particular substrate, and should be determined empirically. A kinase titration experiment such as the one described here will allow you to choose the appropriate amount of kinase for your particular application and determine the amount of kinase (*i.e.*, excess kinase) required to phosphorylate the peptide to saturation. The signal obtained from a peptide phosphorylated to saturation can be used as the 100% phosphorylation control for those users who wish to determine the percent phosphorylation that is occurring in their particular application.

Prepare a kinase titration by diluting stock kinase with the 1X kinase buffer prepared above. Each dilution in the series should be at 4X the final concentration of kinase in the reaction. For kinases supplied from Invitrogen, a 1:10 dilution is suggested as a good starting point for the series. A 10-point, two-fold serial dilution will result in a dose response curve spanning 4 logs.

Template 1 — Kinase Titration Assay (20- μ L reaction)

| Step | Description | Vol. per Reaction |
|------|--|--|
| 1 | To make a Master Mix of everything except active kinase, combine: Kinase Reaction Buffer (10X) Omnia® Peptide Substrate (10X), prepared above ATP Solution (10X), prepared above DTT Solution (10X), prepared above <u>Ultrapure deionized H₂O</u> Total Volume | 2 μ L 2 μ L 2 μ L 2 μ L <u>7 μL</u> 15 μ L |
| 2 | Incubate the Master Mix for 5 minutes at the reaction temperature (kinase-dependent, typically 30°C). | |
| 3 | Warm the assay plate in the plate reader to the reaction temperature (typically 30°C). | |
| 4 | Add 5 μ L of each concentration of 4X kinase to the appropriate wells. | |
| 5 | Aliquot 15 μ L of the Master Mix into each tube or well to start the reactions. Mix well. | |
| 6 | Incubate at 30°C. During incubation, collect fluorescence intensity readings (λ_{ex} 360/ λ_{em} 485) at predetermined intervals (e.g., every 30 seconds for 60 minutes). | |
| 7 | Plot Relative Fluorescence Units (RFU) vs. Time. Choose an optimal kinase concentration for use in additional assays. | |




Figure 2. Representative data from the Omnia® Tyr 7 Assay: Syk was serially diluted and then incubated with Omnia® Tyr 7 peptide for 60 minutes at 30°C. RFU data was collected every 30 seconds and plotted against time. Each line represents a different kinase concentration (μg/mL) as indicated in the legend.

5.3 Kinase Kinetic Activity Analysis

K_m and V_{max} determinations require a kinetic analysis and the generation of a phosphopeptide standard curve. The phosphopeptide standard curve is necessary to convert the RFU signal into a concentration.

To perform the kinetic analysis, combine a fixed concentration of kinase with a serial dilution of peptide substrate. It is important to select a concentration of kinase that will give a linear increase in signal versus time during the initial stages of the kinase reaction. You must empirically determine the exact concentration of kinase required to achieve this linear response via a kinase titration (see **Section 5.2**) and will vary between kinases.

The phosphopeptide standard curve is generated by combining a fixed concentration of kinase with a serial dilution of peptide at the same concentration used in the kinetic assay. Typically the amount of kinase used to generate the phosphopeptide standard curve is higher than the concentration used in the kinetic analysis in order to ensure signal saturation (*i.e.*, 100% phosphorylation of the peptide substrate). The kinase concentration required to reach signal saturation will vary between kinases. A titration of kinase (as outlined in **Section 5.2**) can be performed with the highest concentration of peptide substrate to determine the amount of kinase required to reach saturation.

Peptide substrate preparation: Prepare a two-fold dilution series of substrate using ultrapure water. Each dilution in the series should be at 4X the final concentration of substrate in the reaction. For example, to prepare a dilution with a final substrate concentration of 160 μM, first dilute the 1-mM Omnia® Peptide Substrate to 640 μM (4X) by adding 19.2 μL of Omnia® Peptide Substrate to 10.8 μL of ultrapure water, and then add 5 μL of diluted substrate to the 20 μL reaction as outlined in the following template, for a final concentration of 160 μM.

Reagent preparation: ATP (10X), DTT (10X), and 1X Kinase Reaction Buffer are prepared as described in **Section 5.1**.

Note: K_m determinations frequently require higher substrate concentrations (especially for kinases with K_m s greater than 10 μM).

Template 2 — K_m and V_{max} Determinations (20- μ L reaction)

| Step | Description | Vol. per Reaction |
|------|---|--|
| 1 | Prepare Peptide Control Master Mix: Kinase Reaction Buffer (10X) ATP solution (10X) DTT Solution (10X) <u>Ultrapure deionized H₂O</u> Total Volume | 2 μ L 2 μ L 2 μ L <u>9 μL</u> 15 μ L |
| 2 | Prepare Phosphopeptide Generation Master Mix: Kinase Reaction Buffer (10X) Active Kinase (concentration determined to phosphorylate the highest peptide concentration to saturation) ATP Solution (10X) DTT Solution (10X) <u>Ultrapure deionized H₂O</u> Total Volume | 2 μ L 2 μ L 2 μ L 2 μ L <u>7 μL</u> 15 μ L |
| 3 | Prepare Kinetic Reaction Master Mix: Kinase Reaction Buffer (10X) Active Kinase (concentration determined empirically) ATP Solution (10X) DTT Solution (10X) <u>Ultrapure deionized H₂O</u> Total Volume | 2 μ L 2 μ L 2 μ L 2 μ L <u>7 μL</u> 15 μ L |
| 4 | Incubate the Master Mixes for 5 minutes at the reaction temperature (typically 30°C). | |
| 5 | Warm assay plate in the plate reader to reaction temperature (typically 30°C). | |
| 6 | Add 5 μ L of each serial dilution concentration of Omnia® Peptide Substrate to three sets of wells (one serial dilution for the peptide control, one for the phosphopeptide generation reaction, and one set for the kinetic reaction). | |
| 7 | Aliquot 15 μ L of the Peptide control Master Mix into one of the peptide serial dilution sets, then aliquot 15 μ L of the Phosphopeptide Generation Master Mix into the another peptide serial dilution set, and finally aliquot 15 μ L of the Kinase Reaction Master Mix into the final peptide serial dilution set. Mix well. | |
| 8 | Incubate at 30°C. During incubation, collect fluorescence intensity readings (λ_{ex} 360/ λ_{em} 485) at predetermined intervals (<i>e.g.</i> , every 30 seconds for 60 minutes). | |

5.4 K_m and V_{max} Data Analysis**Step 1. Subtract background**

Subtract the RFU value of the peptide control (*i.e.*, no kinase control) from the RFU value of the kinase reaction for each time point. The RFU value that remains represents the signal from phosphorylated peptide. Since the background fluorescence from the peptide control intensifies at increasing concentrations, the RFU value used for the background subtraction should be from the control peptide at the same concentration as the peptide in the kinase reaction.

Step 2. Determine reaction velocities (v)

Plot the background subtracted RFU values from Step 1 from the kinase reaction versus time and calculate the initial reaction velocities (the slope of the line; RFU/seconds) from the linear portion of the graph.

Step 3. Calculate the slope of the phosphopeptide standard curve

Construct the phosphopeptide standard curve as described in Section 5.3 by graphing the saturating RFU values of each standard curve reaction versus the concentration of peptide substrate in the reaction. Calculate the slope of this standard curve (RFU/ μ M).

Step 4. Convert reaction velocities to $\mu\text{M}/\text{second}$


Convert the reaction velocities to $\mu\text{M}/\text{second}$ by dividing the reaction velocities from Step 2 (RFU/second) by the slope from the phosphopeptide standard curve ($\text{RFU}/\mu\text{M}$) from Step 3.

Step 5. Calculate the K_m and V_{\max}

Using data analysis software, calculate the K_m and V_{\max} by graphing the peptide substrate concentration versus the corrected reaction velocities ($\mu\text{M}/\text{second}$) in a Michaelis-Menten plot and/or prepare a Hanes plot of $([\text{Substrate}]/\text{velocity})$ vs. $[\text{Substrate}]$. See the figures below for examples.

K_m and V_{\max} Sample Data

A. Michaelis-Menten plot



B. Hanes plot




Figure 3. A) Michaelis-Menten plot and B) Hanes plot of experimental results of PKA kinase initial reaction velocities (v) determined at a variety of Omnia[®] Ser/Thr Peptide 2 concentrations ($[\text{S/T Peptide 2}]$ 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM). The resulting kinetic constants derived from these plots were $K_m = 4.5 \mu\text{M}$, $V_{\max} = 1696 \text{ nmoles}/\text{min}/\text{mg}$. For the Hanes plot, K_m is determined by the negative of the x-intercept ($x = -K_m$ when $y = 0$) of the linear fit of the data. V_{\max} is calculated from the y-intercept ($y = K_m/V_{\max}$ when $x = 0$) of the same linear fit and the value of K_m .

5.5 Determining Kinase Inhibitor IC_{50} Values

To determine IC_{50} in the Omnia[®] Assay, plot the initial reaction velocities against a range of inhibitor concentrations.

Note: The compound concentrations should cover at least five orders of magnitude at $\frac{1}{2}$ log intervals.

Note: The inhibitors should be serially diluted in 100% DMSO at 100X and then diluted with 1X Kinase Buffer 1:10 to generate a 10X stock.

Template 3 — Kinase Inhibitor Screening Assay (20- μ L reaction)

| Step | Description | Vol. per Reaction | Vol. per 100 Reactions |
|------|---|---|---|
| 1 | Prepare a Master Mix of everything except active kinase by combining: Kinase Reaction Buffer (10X) Omnia® Peptide Substrate (10X); see Section 5.1 ATP Solution (10X); see Section 5.1 DTT Solution (10X); see Section 5.1 Kinase Inhibitor of interest (10X) <u>Ultrapure deionized H₂O</u> Total Volume | 2 μ L 2 μ L 2 μ L 2 μ L 2 μ L <u>5 μL</u> 15 μ L | 200 μ L 200 μ L 200 μ L 200 μ L 200 μ L <u>500 μL</u> 1500 μ L |
| 2 | Incubate Master Mix for 5 minutes at the reaction temperature (typically 30°C). | | |
| 3 | Warm assay plate in the plate reader to reaction temperature (typically 30°C). | | |
| 4 | Add 5 μ L of 4X kinase to each well to be measured. | | |
| 5 | Aliquot 15 μ L of the Master Mix into each well to start the reactions. Mix well. | | |
| 6 | Incubate at 30°C. During incubation, collect fluorescence intensity readings (λ_{ex} 360/ λ_{em} 485) at predetermined intervals (<i>e.g.</i> , every 30 seconds for 60 minutes). | | |
| 7 | Determine initial reaction velocities (<i>v</i>) for each reaction from the slope of a plot of Relative Fluorescence Units (RFU) vs. Time. | | |
| 8 | Plot velocity vs. [inhibitor] and determine IC ₅₀ . Fit to a sigmoidal dose response curve to obtain the IC ₅₀ , as shown in the graph below. | | |


Syk Inhibition Curve (IC₅₀)

Figure 4: The activity of recombinant Syk was assayed using the Omnia™ Tyr 7 peptide in the presence of increasing concentrations of Staurosporine. The velocity of the reaction (RFUs/sec) was determined and plotted against the Staurosporine concentration.

5.6 Compound Interference

Some samples may contain compounds that interfere with fluorescence and/or activity measurements in this assay. Below is a list of known compounds and their level of interference at specific concentrations:

| Compound | Concentration Tested | % Interference |
|---------------------------------|----------------------|----------------|
| Na ₃ VO ₄ | >0.2 mM | 50% reduction |
| NaCl | 150 mM | 50% reduction |

6. References

Shults, M.D. and Imperiali (2003) Versatile fluorescence probes of protein kinase activity. *J. Am. Chem. Soc.* 125(47): 14248-14249.

Shults, M.D., et al. (2005) A multiplexed homogeneous fluorescence-based assay for protein kinase activity in cell lysates. *Nat. Methods* 2:277-283.

Omnia® is a registered trademark of Life Technologies.

These products are sold under an exclusive license from the Massachusetts Institute of Technology and are covered by patents 10/681,427 and 10/682,427.

©2009 Life Technologies. All rights reserved. For research use only. Not intended for any animal or human therapeutic or diagnostic use.